Skip to main content
. 2022 Oct 16;14(20):5066. doi: 10.3390/cancers14205066

Figure 1.

Figure 1

Overall survival (OS) and progression-free survival (PFS) from the initiation of lenvatinib in the 140 patients included in this study. (a) OS from the initiation of lenvatinib (median survival time, 24.4 months). (b) PFS from the initiation of lenvatinib (median survival time, 9.0 months).